Skip to main content
Log in

Risks of Opioids in ST-Elevation Myocardial Infarction: A Review

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Although opioids are recommended and frequently used in the acute phase of ST-elevation myocardial infarction (STEMI), their use is accompanied by serious side effects. In particular, gastrointestinal adverse effects may disturb absorption of essential oral medication like platelet inhibitors. This may cause suboptimal platelet inhibition and increased risk of acute stent thrombosis. Some clinical studies have already demonstrated these negative results. Alternative strategies to optimize platelet inhibition and pain relief in STEMI are being investigated. Clinicians should become more aware of the potential side effects of opioids in STEMI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.

    Article  Google Scholar 

  2. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr, Chung MK, de Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;124(4):e362–425.

    Google Scholar 

  3. Parodi G. Editor’s Choice-Chest pain relief in patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016;5(3):277–81.

    Article  Google Scholar 

  4. Holzer P. Pharmacology of opioids and their effects on gastrointestinal function. Am J Gastroenterol Suppl. 2014;2:9–16.

    Article  Google Scholar 

  5. Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA. 1993;90(12):5391–3.

    Article  CAS  Google Scholar 

  6. Headrick JP, See Hoe LE, Du Toit EF, Peart JN. Opioid receptors and cardioprotection—’opioidergic conditioning’ of the heart. Br J Pharmacol. 2015;172(8):2026–50.

    Article  CAS  Google Scholar 

  7. Sobanski P, Krajnik M, Shaqura M, Bloch-Boguslawska E, Schafer M, Mousa SA. The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue. Heart Vessels. 2014;29(6):855–63.

    Article  Google Scholar 

  8. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–73.

    Article  CAS  Google Scholar 

  9. Kubo S, Kadota K, Ichinohe T, Miyake K, Hyodo Y, Otsuru S, et al. Comparison of long-term outcome after percutaneous coronary intervention for stent thrombosis between early, late, and very late stent thrombosis. Circ J. 2014;78(1):101–9.

    Article  Google Scholar 

  10. Claessen BE, Henriques JP, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv. 2014;7(10):1081–92.

    Article  Google Scholar 

  11. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther. 2001;89(2):123–37.

    Article  CAS  Google Scholar 

  12. Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M, et al. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv. 2010;3(1):49–55.

    Article  Google Scholar 

  13. Johnson MW, Mitch WE, Wilcox CS. The cardiovascular actions of morphine and the endogenous opioid peptides. Prog Cardiovasc Dis. 1985;27(6):435–50.

    Article  CAS  Google Scholar 

  14. Coltart DJ, Malcolm AD. Pharmacological and clinical importance of narcotic antagonists and mixed antagonists–use in cardiology. Br J Clin Pharmacol. 1979;7(Suppl 3):309S–11S.

    Article  Google Scholar 

  15. McCarthy CP, Mullins KV, Sidhu SS, Schulman SP, McEvoy JW. The on- and off-target effects of morphine in acute coronary syndrome: a narrative review. Am Heart J. 2016;176:114–21.

    Article  CAS  Google Scholar 

  16. Herlitz J, Hjalmarson A, Waagstein F. Treatment of pain in acute myocardial infarction. Br Heart J. 1989;61(1):9–13.

    Article  CAS  Google Scholar 

  17. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37(3):245–52.

    Article  CAS  Google Scholar 

  18. Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–55.

    Article  CAS  Google Scholar 

  19. Feng XQ, Zhu LL, Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res. 2017;24(10):1225–39.

    Article  Google Scholar 

  20. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;8:e001593.

    PubMed  Google Scholar 

  21. Hozumi J, Egi M, Sugita S, Sato T. Dose of intraoperative remifentanil administration is independently associated with increase in the risk of postoperative nausea and vomiting in elective mastectomy under general anesthesia. J Clin Anesth. 2016;34:227–31.

    Article  CAS  Google Scholar 

  22. Yoo YC, Na S, Jeong JJ, Choi EM, Moon BE, Lee JR. Dose-dependent attenuation by fentanyl on cough during emergence from general anesthesia. Acta Anaesthesiol Scand. 2011;55(10):1215–20.

    Article  CAS  Google Scholar 

  23. Chen J, Li W, Wang D, Hu X. The effect of remifentanil on cough suppression after endoscopic sinus surgery: a randomized study. Acta Anaesthesiol Scand. 2010;54(10):1197–203.

    Article  CAS  Google Scholar 

  24. Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17(Suppl. 11):S276–87.

    PubMed  Google Scholar 

  25. Johnson TW, Mumford AD, Scott LJ, Mundell S, Butler M, Strange JW, et al. A study of platelet inhibition, using a ‘point of care’ platelet function test, following primary percutaneous coronary intervention for ST-elevation myocardial infarction [PINPOINT-PPCI]. PLoS One. 2015;10(12):e0144984.

    Article  Google Scholar 

  26. Xanthopoulou I, Davlouros P, Tsigkas G, Koutsogiannis N, Patsilinakos S, Deftereos S, et al. Factors affecting platelet reactivity 2 hours after P2Y(1)(2) receptor antagonist loading in primary percutaneous coronary intervention for ST-elevation myocardial infarction—impact of pain-to-loading time. Circ J. 2016;80(2):442–9.

    Article  CAS  Google Scholar 

  27. McEvoy JW, Ibrahim K, Kickler TS, Clarke WA, Hasan RK, Czarny MJ, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial (Platelet Aggregation with Ticagrelor Inhibition and Fentanyl). Circulation. 2018;137(3):307–9.

    Article  CAS  Google Scholar 

  28. Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost. 2016;116(2):369–78.

    Article  Google Scholar 

  29. Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NN, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost. 2016;116(1):96–102.

    Article  Google Scholar 

  30. de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Urban D, et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol. 2015;104(9):727–34.

    Article  Google Scholar 

  31. Gwag HB, Park TK, Song YB, Kim EK, Jang WJ, Yang JH, et al. Morphine does not affect myocardial salvage in ST-segment elevation myocardial infarction. PLoS One. 2017;12(1):e0170115.

    Article  Google Scholar 

  32. Bellandi B, Zocchi C, Xanthopoulou I, Scudiero F, Valenti R, Migliorini A, et al. Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol. 2016;15(221):567–71.

    Article  Google Scholar 

  33. Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, Cayla G, et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J. 2016;37(13):1063–71.

    Article  Google Scholar 

  34. Bonin M, Mewton N, Roubille F, Morel O, Cayla G, Angoulvant D, et al. Effect and safety of morphine use in acute anterior ST-segment elevation myocardial infarction. J Am Heart Assoc. 2018;7(4):e006833.

    Article  Google Scholar 

  35. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149(6):1043–9.

    Article  CAS  Google Scholar 

  36. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303–13.

    Article  CAS  Google Scholar 

  37. Venetsanos D, Sederholm Lawesson S, Swahn E, Alfredsson J. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thromb Res. 2017;149:88–94.

    Article  CAS  Google Scholar 

  38. Crean B, Finnie C, Crosby A. Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo. Drugs R D. 2013;13(2):153–7.

    Article  Google Scholar 

  39. Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65(5):511–2.

    Article  Google Scholar 

  40. Rollini F, Franchi F, Hu J, Kureti M, Aggarwal N, Durairaj A, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH Study. J Am Coll Cardiol. 2016;67(17):1994–2004.

    Article  CAS  Google Scholar 

  41. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–9.

    Article  CAS  Google Scholar 

  42. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 2002;106(2):167–9.

    Article  Google Scholar 

  43. Shau WY, Chen HC, Chen ST, Chou HW, Chang CH, Kuo CW, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan’s National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord. 2012;12:4-2261-12-4.

    Article  Google Scholar 

  44. Cantais A, Schnell D, Vincent F, Hammouda Z, Perinel S, Balichard S, et al. Acetaminophen-induced changes in systemic blood pressure in critically ill patients: results of a multicenter cohort study. Crit Care Med. 2016;44(12):2192–8.

    Article  CAS  Google Scholar 

  45. Chiam E, Weinberg L, Bailey M, McNicol L, Bellomo R. The haemodynamic effects of intravenous paracetamol (acetaminophen) in healthy volunteers: a double-blind, randomized, triple crossover trial. Br J Clin Pharmacol. 2016;81(4):605–12.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anne Henrieke Tavenier.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this study.

Conflict of interest

Anne Henrieke Tavenier, Renicus Suffridus Hermanides, Jan Paul Ottervanger, Peter Gerrit Johannes Ter Horst, Elvin Kedhi, Adriaan W. J. van ‘t Hof have no conflicts of interest that are directly relevant to the content of this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tavenier, A.H., Hermanides, R.S., Ottervanger, J.P. et al. Risks of Opioids in ST-Elevation Myocardial Infarction: A Review. Drug Saf 41, 1303–1308 (2018). https://doi.org/10.1007/s40264-018-0710-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-018-0710-y

Navigation